Effects of exercise training and diet restriction on cardiovascular function in obese population

Effects of an 8-week combined exercise and diet intervention on endothelial function, autonomic function and arterial stiffness in obese adults

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN83594346

Enrollment

Registered

2017-04-28

Start date

2016-04-01

Completion date

Unknown

Last updated

2023-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity Nutritional, Metabolic, Endocrine Obesity

Interventions

Obese subjects (BMI = 30 kg/m2) were recruited from the weight loss camp after physical examination. The weight loss camp was totally closed with uniformly managed accommodation, diet and training dur

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Obese adults who had a body mass index (BMI) = 30 kg/m2) 2. Aged 18 and over

Exclusion criteria

Exclusion criteria: 1. Unstable angina pectoris 2. Myocardial infarction within the last 12 months 3. Decompensated heart failure 4. Cardiomyopathy 5. Severe valvular heart disease 6. Considerable pulmonary disease 7. Uncontrolled hypertension 8. Kidney failure 9. Orthopaedic and/or neurological limitations to exercise 10. Surgery during the intervention period 11. Drug or alcohol abuse

Design outcomes

Primary

Measure	Time frame
1. Endothelial function, assessed by flow-mediated dilation (FMD) 2. Circulating endothelial progenitor cells levels, evaluated by flow cytometry 3. Heart rate variability (HRV), aortic pressure, augmentation pressure, augmentation index, measured using the SphygmoCor device (AtCor Medical, Sydney, Australia) 4. Pulse wave velocity (PWV), measured using both the SphygmoCor device and an oscillometric device (boso ABI-system 100; BOSCH & SOHN, Germany) Measurements performed before and after the 8-week combined exercise training and diet intervention.	—

Measure

Time frame

1. Endothelial function, assessed by flow-mediated dilation (FMD) 2. Circulating endothelial progenitor cells levels, evaluated by flow cytometry 3. Heart rate variability (HRV), aortic pressure, augmentation pressure, augmentation index, measured using the SphygmoCor device (AtCor Medical, Sydney, Australia) 4. Pulse wave velocity (PWV), measured using both the SphygmoCor device and an oscillometric device (boso ABI-system 100; BOSCH & SOHN, Germany) Measurements performed before and after the 8-week combined exercise training and diet intervention.

—

Secondary

Measure	Time frame
1. Body composition determined using a body composition analyzer (Inbody 370, Biospace, Seoul, Korea) 2. Resting heart rate (HR) and brachial systolic/diastolic blood pressure (bSBP/bDBP), measured using a sphygmomanometer 3. Aerobic fitness, assessed using the Physical Working Capacity at a heart rate of 150 beats per minute (PWC150) or a heart rate of 170 beats per minute (PWC170) cycle ergometer test (Ergoselect 100, Ergoline, Bitz, Germany) 4. Circulating irisin levels, measured using irisin ELISA kit (Phoenix Pharmaceuticals, CA, USA) following the manufacturer’s instructions 5. Concentrations of vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), adiponectin, tumor necrosis factor-alpha (TNF-a), high-sensitivity C-reactive protein (hsCRP) and superoxide dismutase (SOD) in serum, analyzed using ELISA Kits respectively (Cusabio, Biotech. Co., LTD, Wuhan, China) according to the manufacturer’s instructions Measurements performed before and after the 8-week combined exercise training and diet intervention.	—

Measure

Time frame

1. Body composition determined using a body composition analyzer (Inbody 370, Biospace, Seoul, Korea) 2. Resting heart rate (HR) and brachial systolic/diastolic blood pressure (bSBP/bDBP), measured using a sphygmomanometer 3. Aerobic fitness, assessed using the Physical Working Capacity at a heart rate of 150 beats per minute (PWC150) or a heart rate of 170 beats per minute (PWC170) cycle ergometer test (Ergoselect 100, Ergoline, Bitz, Germany) 4. Circulating irisin levels, measured using irisin ELISA kit (Phoenix Pharmaceuticals, CA, USA) following the manufacturer’s instructions 5. Concentrations of vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), adiponectin, tumor necrosis factor-alpha (TNF-a), high-sensitivity C-reactive protein (hsCRP) and superoxide dismutase (SOD) in serum, analyzed using ELISA Kits respectively (Cusabio, Biotech. Co., LTD, Wuhan, China) according to the manufacturer’s instructions Measurements performed before and after the 8-week combined exercise training and diet intervention.

—

Countries

China

Contacts

Public ContactDan Wang

17880383@qq.com+86 (0)20 3802 5087

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026